In light of this information, the presence of MEFV mutation as a modifier factor in IBD should be considered and evaluated in terms of its association with clinical severity and disease complications, such as secondary amyloidosis, especially in patients who do not respond to potent immunosuppressive treatments and require surgery. The gene discussed is MEFV; the disease is AA amyloidosis.